A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination With a Ritonavir-Containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus OBT Over 48 Weeks.

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination With a Ritonavir-Containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus OBT Over 48 Weeks.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Aplaviroc (Primary) ; Antiretrovirals; Ritonavir
  • Indications HIV infections
  • Focus Therapeutic Use
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 28 Mar 2011 Planned end date (Oct 2005) added as reported by ClinicalTrials.gov.
    • 21 May 2009 New source identified and integrated (ClinicalTrials.gov record NCT00197145)
    • 14 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top